Compare Eli Lilly And Co (LLY) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Global X SuperDividend ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Global X SuperDividend ETF trades at $23.96 (market cap $1.17B). The key difference: Eli Lilly And Co is far larger — about 888.9× Global X SuperDividend ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Global X SuperDividend ETF for 47 Days on average.
| LLY | SDIV | |
|---|---|---|
Market Cap | $1.04T | $1.17B |
Volume | 3,064,878 | 387,692 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $26.34 |
52-Week Low | $799.57 | $22.90 |
Typical Hold Time | 93 Days | 47 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SDIV trades at $23.96, up 1.61% with a bearish technical outlook from moving averages. The ETF maintains an 8%+ dividend yield but faces significant price erosion, having lost 66% since inception according to Seeking Alpha (2026-09-11). Recent institutional buying includes Ameritas Advisory Services increasing its position by 92.6% in Q2 2026. Technical indicators show mixed signals with neutral oscillators but bearish moving averages and ADX readings.
SDIV offers high income potential but carries substantial principal risk. The fund's deep value approach lacks quality screening, leading to persistent underperformance versus global benchmarks. While monthly dividends attract income seekers, the erosion of capital requires careful risk assessment for long-term investors considering this high-yield strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
